Pitcairn Co. Raises Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Pitcairn Co. increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 1.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,378 shares of the company’s stock after buying an additional 78 shares during the quarter. Pitcairn Co.’s holdings in TransMedics Group were worth $398,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of TMDX. First Horizon Advisors Inc. grew its position in TransMedics Group by 26.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after acquiring an additional 222 shares in the last quarter. Park Avenue Securities LLC grew its holdings in TransMedics Group by 3.4% during the 1st quarter. Park Avenue Securities LLC now owns 11,374 shares of the company’s stock valued at $841,000 after purchasing an additional 372 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in TransMedics Group during the 1st quarter worth $30,000. ProShare Advisors LLC lifted its holdings in TransMedics Group by 7.8% in the 1st quarter. ProShare Advisors LLC now owns 5,871 shares of the company’s stock worth $434,000 after buying an additional 427 shares in the last quarter. Finally, Fidelis Capital Partners LLC purchased a new position in TransMedics Group in the 1st quarter valued at about $35,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Stock Down 2.1 %

TransMedics Group stock traded down $3.20 during midday trading on Thursday, hitting $145.99. The stock had a trading volume of 470,395 shares, compared to its average volume of 739,061. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. The stock has a market cap of $4.81 billion, a P/E ratio of -437.79 and a beta of 1.98. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $156.05. The business has a fifty day moving average price of $143.16 and a 200 day moving average price of $108.24.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.40. The firm had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. TransMedics Group’s quarterly revenue was up 132.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.08) earnings per share. Research analysts predict that TransMedics Group, Inc. will post 0.81 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Piper Sandler lifted their target price on TransMedics Group from $120.00 to $170.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. Morgan Stanley boosted their price target on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Canaccord Genuity Group boosted their price target on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. TD Cowen boosted their price target on TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Finally, Cantor Fitzgerald began coverage on TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $146.38.

Insider Activity

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James R. Tobin sold 15,040 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $106.43, for a total value of $1,600,707.20. Following the transaction, the director now directly owns 205,171 shares of the company’s stock, valued at $21,836,349.53. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 247,667 shares of company stock valued at $30,087,968. 7.00% of the stock is currently owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.